Science and technology

University of Sydney Researchers Develop Experimental Nasal Drops to Improve Memory in Mice

20 November 20265 min read

University of Sydney Researchers Develop Experimental Nasal Drops to Improve Memory in Mice
An experimental mRNA-based treatment improved memory and learning and boosted nerve cell growth in aged mice and in mice genetically modified to mimic…

Researchers at Australia's University of Sydney have achieved promising results in developing an experimental treatment in the form of nasal drops, based on messenger RNA (mRNA) technology. The treatment showed an ability to improve memory and learning and to boost the growth of nerve cells in aged mice and in mice genetically modified to mimic Alzheimer's disease.

The university said in a statement published on Thursday that the study, published in the scientific journal "Advanced Science", showed that the treatment stimulates nasal cells to produce the protein "brain-derived neurotrophic factor" (BDNF). This protein plays an important role in supporting the survival and function of nerve cells and in enhancing learning and memory formation, through mRNA molecules loaded inside lipid nanoparticles.

Results of the mouse experiments

Experiments on aged mice that received the drops showed improvement in memory and learning tests, with their performance approaching the levels of young mice. Their brains also showed a 2.4-fold increase in cells linked to the formation of new nerve cells compared with the control group.

In other experiments on mice genetically modified to mimic Alzheimer's disease, the researchers observed improved cognitive performance and memory, along with higher indicators of nerve cell growth in the hippocampus, the region responsible for learning and memory. No clear reduction was recorded in the amyloid deposits associated with the disease, which suggests that the treatment's effect may be linked to supporting the function and health of nerve cells, rather than directly targeting those deposits.

How the technology works

The study's leader, Professor Greg Neely, explained that the technology relies on delivering genetic instructions to nasal cells to stimulate them to produce the therapeutic protein. He added that this protein can reach the brain via neural pathways linked to the nasal cavity, thereby bypassing the blood-brain barrier, which limits the access of many drugs to brain tissue.

The next stage

The treatment is still at the animal testing stage, as moving to human studies requires completing safety and efficacy tests. The researchers expect clinical trials could begin within the next two years, and if proven successful, this technology could open new avenues for studying treatments for memory disorders and age-related neurodegenerative diseases.

Source: Syrian Arab News Agency (SANA)

Comments (0)

0 / 600
No comments yet. Be the first to comment.